| 1/43 | US=348 / Tese/FAP Chiappini PBO. Estudo da expressão de mTOR, PTEN e AKT na mucosa gástrica normal e carcinomas gástricos. [Study of the expression of mTOR, PTEN and AKT normal mucosa and gastric carcinomas]. São Paulo, 2011. 86 p. Dissertação(Mestrado)-Fundação Antônio Prudente. Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2011/PaulaChiappini/PaulaChiappini.pdf NEOPLASIAS GASTRICAS; MARCADORES BIOLOGICOS; IMUNOISTOQUIMICA; PTEN FOSFOIDROLASE; PROTEINAS PROTO-ONCOGENICAS C-AKT; MTOR |
| 2/43 | US=94 / Biol/Mol Matthews DJ, Gerritsen ME. Intracellular signal transduction cascades. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 265-325. ISBN 978-0-470-22965-1. TRANSDUCAO DE SINAIS INTRACELULARES; PI3K; FOSFATIDILINOSITOL 3-QUINASE; PTEN; PDK1; DESIDROGENASE PIRUVATO LIPOAMIDE QUINASE ISOENZIMA 1; AKT; CANCER; CANCER DE MAMA; CANCER COLORRETAL; CANCER ENDOMETRIAL; CARCINOMA GASTRICO; GLIOBLASTOMA; CARCINOMA HEPATOCELULAR; CANCER DE PULMAO; MELANOMA; CANCER DE OVARIO; CANCER DE PANCREAS; CARCINOMA DE PROSTATA; CARCINOMA DE TIREOIDE; NEOPLASIAS HEMATOLOGICAS; MTOR; QUINASE P70S6; PROTEINA QUINASE ATIVADA POR MITOGENO (MAPK); ERK; FAMILIA QUINASE RAF; MEK; PIM; PROTEINA QUINASE C (PKC) |
| 3/43 | US=94 / Biol/Mol Matthews DJ, Gerritsen ME. Intracellular signaling kinase inhibitors. In: ___. Targeting protein kinases for cancer therapy. New Jersey: Wiley, 2010. p. 567-621. ISBN 978-0-470-22965-1. INIBIDORES DE QUINASES; SINALIZACAO INTRACELULAR; INIBIDORES MTOR; INIBIDORES PI3K; INIBIDORES RAF; INIBIDORES MEK; INIBIDORES CDK; CICLO CELULAR; INIBIDORES PLK; INIBIDORES QUINASE-AURORA; INIBIDORES PROTEINA QUINASE C |
| 4/43 | US=32 / Gastro Villanueva A, Alsinet C, Llovet JM. Signaling pathways and rationale for molecular therapies in hepatocellular carcinoma. In: Clavien PA, Breitenstein S. Malignant liver tumors: current and emerging therapies. 3ª ed. New Jersey: John Wiley & Sons, 2010. p. 368-81. ISBN 978-1-4051-7976-8. CARCINOMA HEPATOCELULAR; VIAS DE SINALIZACAO; TERAPIA MOLECULAR; CARCINOMA HEPATOCELULAR. PATOGENESE MOLECULAR; INIBIDORES DA TIROSINA QUINASE; INIBIDORES MTOR; INIBIDORES DA ANGIOGENESE |
| 5/43 | US=32 / Gastro Huitzil-Melendez FD, Abou-Alfa GK, Morse MA. Novel therapies targeted at sinal transduction in liver tumors. In: Clavien PA, Breitenstein S. Malignant liver tumors: current and emerging therapies. 3ª ed. New Jersey: John Wiley & Sons, 2010. p. 382-92. ISBN 978-1-4051-7976-8. CANCER DE FIGADO; TRANSDUCAO DE SINAL; RECEPTORES TIROSINA QUINASE (RTK); RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO INSULIN-LIKE (IGF-I); PROTO-ONCOGENE C-MET; VIAS INTRACELULARES DE TRANSDUCAO DE SINAL; MAPK; PI3K; AKT; MTOR; FAMILIA RAS; WNT/B-CATENIN; ANGIOGENESE |
| 6/43 | US=9 / Urologia Rosenberg J. Beyond Docetaxel: emerging agents in the treatment of advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 147-51. ISBN 978-1-60327-831-7. DOCETAXEL; CANCER DE PROSTATA AVANCADO; INIBICAO DE MTOR; NOVAS TERAPEUTICAS; DESACETILACAO DAS HISTONAS; HSP90; FATOR 1 DE CRESCIMENTO COM INSULINA |
| 7/43 | US=2 / Ginecologia Muggia F, Gold LI, Curtin J. Future directions: new targets. In: Muggia F, Oliva E. Uterine cancer: screening, diagnosis, and treatment. New York: Humana Press, 2009. p. 267-83. ISBN 978-1-588-29-736-5. ALVOS MOLECULARES; IMUNOTERAPIA; PTEN; MTOR; HORMONIO; RECEPTORES |
| 8/43 | US=14 / Dermatologia Geissler EK. Immunosuppression. In: Ulrich ESC, Euvrard S, Proby C, Bavinck JNB, Geissler EK. Skin cancer after organ transplantation. New York: Springer, 2009. p. 23-43. (Cancer Treatment and Reseach) ISBN 978-0-387-78573-8. CANCER DE PELE; TRANSPLANTE; IMUNOSSUPRESSAO; IMUNOSSUPRESSAO DE TRANSPLANTES. HISTORICO; IMUNOSSUPRESSAO FARMACOLOGICA; INIBIDORES DA CALCINEURINA; ACIDO MICOFENOLICO; INIBIDOR DE MTOR; AZATIOPRINA; CORTICOSTEROIDE; FTY720; OKT3; TIMOGLOBULINA; INTERLEUCINA-2 (IL-2); ALEMTUZUMAB; CAMPATH-1H |
| 9/43 | US=14 / Dermatologia Perrett CM, Harwood CA, McGregor JM, Karran P. Carcinogenic mechanisms related to immunosuppressive therapy. In: Ulrich ESC, Euvrard S, Proby C, Bavinck JNB, Geissler EK. Skin cancer after organ transplantation. New York: Springer, 2009. p. 123-32. (Cancer Treatment and Reseach) ISBN 978-0-387-78573-8. MECANISMOS CANCERIGENOS; TERAPIA IMUNOSSUPRESSORA; CARCINOGENESE; GLUCOCORTICOIDES; CICLOSPORINA; AZATIOPRINA; INIBIDORES DE MTOR |
| 10/43 | US=14 / Dermatologia Morelon E, Mahe E, Touraine JL. The role of the transplant physician in the management of skin cancers after organ transplantation. In: Ulrich ESC, Euvrard S, Proby C, Bavinck JNB, Geissler EK. Skin cancer after organ transplantation. New York: Springer, 2009. p. 377-90. (Cancer Treatment and Reseach) ISBN 978-0-387-78573-8. CANCER DE PELE; RESPONSABILIDADE MEDICA; TRANSPLANTE DE ORGAOS; CLINICO DE TRANSPLANTE; IMUNOSSUPRESSAO; INIBIDORES DE MTOR; CANCER DE PELE NAO MELANOMA |
| 11/43 | US=6 / Quimioterapia Airley R. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR). In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 245-8. ISBN 978-0-470-09254-5. CHECKPOINT; PROTEINAS QUINASES; MTOR; ALVO DA RAPAMICINA EM MAMIFEROS; ATIVACAO DE MTOR; ANTICANCERIGENOS ALVO MTOR |
| 12/43 | US=22 / Urologia Junior Kaelin WG, Geoge DJ. The molecular biology of kidney cancer and its clinical translation into treatment strategies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 79-97. ISBN 978-1-58829-737-2. VON HIPPEL-LINDAU; HIPOXIA; ANGIOGENESE; HIF; VEGF; KDR; MTOR |
| 13/43 | US=22 / Urologia Cho D, Mier JW, Atkins MB. PI3K/AKt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 267-85. ISBN 978-1-58829-737-2. INIBIDORES PI3K; RCC; HIPERATIVACAO DO AKT/PI3K; ATIVIDADE AKT; TEMSIROLIMUS |
| 14/43 | US=35 / Gastro Kiguchi K, DiGiovanni J. Role of growth factor-signaling pathways. In: Thomas CR Junior, Fuller CD. Biliary tract and gallbladder cancer: diagnosis and therapy. New Jersey: DemosMedical, 2009. p. 19-34. ISBN 978-1-933864-42-6. NEOPLASIAS DO TRATO BILIAR; CANCER DE VESICULA BILIAR; FATOR DE CRESCIMENTO; FAMILIA ERBB; RECEPTOR DO FATOR DE CRESCIMENTO INSULIN-LIKE 1; C-MET; MTOR; COX-2 |
| 15/43 | US=85 / Biol/Mol Plantivaux A, Szegezdi E, Samali A, Egan L. Is there a role for nuclear factor kB in tumor necrosis factor-related apoptosis-inducing ligand resistance?. In: Diederich M. Natural compounds and their role in apoptotic cell signaling pathways. Boston: Blackwell, 2009. p. 38-49. (Annals of the New York Academy of Sciences Vol 1171) ISBN 978-1-57331-737-5. CANCER; APOPTOSE; RESISTENCIA; INIBIDORES DE PROTEASSOMA; SUPER-REPRESSOR; MTOR; TRAIL; NF-KB |
| 16/43 | US=103 / Câncer Bradshaw TD. Target-directed drug discovery. In: Missailidis S. Anticancer therapeutics. New Jersey: Wiley Blackwell, 2008. p. 223-43. ISBN 978-0-470-72303-6. TERAPIA ALVO-DIRIGIDA; TIROSINA-QUINASES; CANCER DE PULMAO DE CELULAS NAO PEQUENAS; LEUCEMIA MIELOIDE CRONICA; CANCER DE MAMA; ANGIOGENESE; CICLO CELULAR; APOPTOSE; MTOR |
| 17/43 | US=35 / Biol/Mol Levine AJ, Hu W, Feng Z. Tumor suppressor genes. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 31-8. ISBN 978-1-4160-3703-3. |
| 18/43 | US=35 / Biol/Mol Guertin DA, Sabatini DM. Cell growth. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 169-75. ISBN 978-1-4160-3703-3. CRESCIMENTO CELULAR; VIAS BIOQUIMICAS DO CONTROLE DE CRESCIMENTO; MTOR |
| 19/43 | US=67 / Biol/Mol Easton JB, Houghton PJ. mTOR: properties and therapeutics. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 33-53. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MTOR; PROPRIEDADES; TERAPEUTICA; INIBIDORES; RAPAMICINA; CANCER; ENSAIOS CLINICOS |
| 20/43 | US=69 / Câncer Zurita AJ, Ward JF, Kim J. Targeted therapy in prostate cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 289-304. ISBN 978-1-60327-423-4. TERAPIA-ALVO; CANCER DE PROSTATA; CANCER DE PROSTATA; NEOPLASIA DE PROSTATA; RESISTENTE A CASTRACAO CANCRO DA PROSTATA; ANDROGENO RECEPTOS; ANSAMICINAS; MTOR; ANGIOGENESE; IMUNOTERAPIA |
